Product Information
LAMIVUDINE 300 MG TABLET is a generic product labeled by Aurobindo Pharma Limited, priced at $1.3014 per EA under NDC 65862002630. Its NADAC has been published 324 times since Apr 18, 2018.
FDA first approved this application on Nov 21, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
300 mg/1
Manufacturer
Aurobindo Pharma LimitedNDC
65862002630
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
8/20/2025
Active Ingredients
LAMIVUDINEApproval Type
Generic (ANDA)
FDA Application
ANDA077464FDA Approved
11/21/2016
TE Code
AB
On Market Since
11/21/2016
Pharmacological Classes
Price Statistics
The NADAC for LAMIVUDINE 300 MG TABLET has been published 324 times since Apr 18, 2018, and over the history we have for it it has declined 58.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.3014 per EA |
|---|---|
| All-time high | $3.0970 (Jun 13, 2018) |
| All-time low | $1.1052 (Jan 22, 2020) |
| Median price | $1.6132 |
| Average price | $1.6516 |
| Largest weekly change | +54.2% (Feb 17, 2021) |
| Weeks tracked | 324 |
| Tracking since | Apr 18, 2018 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
+0.7%
5Y
-25.9%
All
-58.0%
Last surveyed Aug 20, 2025 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of LAMIVUDINE 300 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for LAMIVUDINE 300 MG TABLET, manufactured by Aurobindo Pharma Limited, is $1.3014 per EA (NDC 65862002630), effective Aug 20, 2025.
How has the price of LAMIVUDINE 300 MG TABLET changed over time?
Over the history we have for it, the NADAC for LAMIVUDINE 300 MG TABLET has declined 58.0%. It has been tracked across 324 weekly CMS publications since Apr 18, 2018.
What are the highest and lowest recorded NADAC prices for LAMIVUDINE 300 MG TABLET?
Since Apr 18, 2018, the NADAC for LAMIVUDINE 300 MG TABLET has ranged from a low of $1.1052 (Jan 22, 2020) to a high of $3.0970 (Jun 13, 2018), with a median of $1.6132 per EA.
Are there cheaper alternatives to LAMIVUDINE 300 MG TABLET?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as LAMIVUDINE 300 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures LAMIVUDINE 300 MG TABLET?
LAMIVUDINE 300 MG TABLET (NDC 65862002630) is labeled by Aurobindo Pharma Limited, and CMS classifies it as a generic product.